Cisplatin and Doxorubicin as Second-Line Therapy in Ovarian Cancer

InPharma ◽  
1984 ◽  
Vol 447 (1) ◽  
pp. 9-9
Keyword(s):  
Ovarian Cancer ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer

1992 ◽  
Vol 47 (3) ◽  
pp. 282-286 ◽  
Author(s):  
Ignace Vergote ◽  
Anna Himmelmann ◽  
Bo Frankendal ◽  
Marit Scheistrøen ◽  
Kerstin Vlachos ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

Paclitaxel vs Epidoxorubicin plus Paclitaxel as Second-Line Therapy for Platinum-Refractory and -Resistant Ovarian Cancer

1999 ◽  
Vol 72 (1) ◽  
pp. 60-64 ◽  
Author(s):  
Giorgio Bolis ◽  
Fabio Parazzini ◽  
Giovanna Scarfone ◽  
Antonella Villa ◽  
Mariangela Amoroso ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy ◽  
Platinum Refractory

scholarly journals Phase II Clinical Study on the GEMOX Regimen as Second-line Therapy for Advanced Ovarian Cancer

2013 ◽  
Vol 14 (6) ◽  
pp. 3949-3953 ◽  
Author(s):  
Shao-Fei Yuan ◽  
Lian-Ping Zhang ◽  
Lin-Jia Zhu ◽  
Wen-Jun Chen ◽  
Wei-E Zheng ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Study ◽  
Phase Ii ◽  
Advanced Ovarian Cancer ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy ◽  
Phase Ii Clinical Study

A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer

2005 ◽  
Vol 23 (1) ◽  
pp. 85-89 ◽  
Author(s):  
Francesco Caponigro ◽  
Pax Willemse ◽  
Roberto Sorio ◽  
Anne Floquet ◽  
Simon van Belle ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Locally Advanced ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document